Piera Gargiulo

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Quincy S. Chu, Laurent Greillier, Wei Tu et al. · The Lancet · 2023 · 86 citations

Chemotherapy Versus Chemotherapy, Oncology, Pathology +5

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial

Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino et al. · Journal of Thoracic Oncology · 2022 · 63 citations · Full text

Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial

Antonio González-Martı́n, Christophe Desauw, Florian Heitz et al. · European Journal of Cancer · 2022 · 63 citations · Full text

Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis

Marta Bonotto, Lorenzo Gerratana, Massimo Di Maïo et al. · The Breast · 2016 · 55 citations · Full text

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

Sandro Pignata, Giovanni Scambia, Clorinda Schettino et al. · The Lancet Oncology · 2023 · 46 citations

Medicine, Cancer Management, Mito End-3 +7